Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Status:
Not yet recruiting
Trial end date:
2022-11-08
Target enrollment:
Participant gender:
Summary
Primary Objectives
1.Evaluation of safety and tolerability after repeated administration of injectable
Lipivirtide in HIV-infected patients not receiving antiretroviral therapy
Secondary Objectives
1. Evaluation of the pharmacokinetic properties of injectable Lipovirtide after multiple
administrations in HIV-infected patients not receiving antiretroviral therapy, to obtain
pharmacokinetic parameters.
2. Evaluation of the efficacy of injectable Lipovirtide for HIV in HIV-infected patients
not receiving antiretroviral therapy.
3. Evaluation of the immunogenicity of lipovirtide for injection.
Phase:
Phase 1
Details
Lead Sponsor:
Shanxi Kangbao Biological Product Co., Ltd.
Collaborator:
Institute of Pathogen Biology, Chinese Academy of Medical Sciences